POLD1 DEDD Motif Mutation Confers Hypermutation in Endometrial Cancer and Durable Response to Pembrolizumab.
Christina Hsiao WeiEdward Wenge WangLingzi MaYajing ZhouLi ZhengHeather HampelSusan ShehayebStephen LeeJoshua CohenAdrian KohutFang FanSteven RosenXiwei WuBinghui ShenYuqi ZhaoPublished in: Cancers (2023)
is detrimental to DNA proofreading and should be reclassified as likely pathogenic and possibly predictive of ICI sensitivity.